Asia Pacific Ocular Drug Delivery Market

Market Introduction

Asia Pacific consists of five major countries namely China, Japan, India, Australia, and South Korea. The market is also evaluated for the rest of countries in Asia Pacific. Japan holds the largest share of the Asia Pacific ocular drug delivery market. In Japan, a substantial increase or the higher increase in incidences of normal-tension glaucoma (NTG), which is a form of glaucoma, is found. The prevalence of glaucoma is majorly observed in the elderly population; until 2017, nearly four million people were registered for glaucoma in Japan. The country has improved its glaucoma treatment regimen. The improvement has introduced new antiglaucoma ophthalmic solutions and minimally invasive glaucoma surgeries for patients across the country. Similarly, the country has a considerable number of patients with a dry eye disease (DED), various studies were conducted in the country for dry eye disease. The results of the studies showed that the prevalence of the DED among the Japanese I relatively higher. The annual health plan cost was estimated at nearly US$ 323 for every patient in the country. Additionally, the country has rising numbers of diabetes patients, which is another leading cause of diabetic retinopathy. Among Japan's total population, nearly 7.7% of people living with diabetes are approximately 7.2 million adults in the country. The country is facing a decreasing number of ophthalmologists in the country. However, the country is among the important country in terms of the developments for the healthcare infrastructure.

The 2019 novel coronavirus (2019-nCoV), officially named COVID-19 by the WHO, has spread to more than 170 countries, including China prompting the WHO to declare the disease as a global pandemic. COVID-19 has had a tremendous impact on eye care delivery across the Asia Pacific region. In Bangladesh, all routine elective eye surgeries were postponed. Only emergency eye treatment was conducted only at outpatient departments. Moreover, patients were allowed to go to hospital only in the case of emergency. Similarly in India, outreach eye health services stopped largely thus impacting the rural communities. All elective surgeries were postponed. Non-cataract conditions like diabetic retinopathy and glaucoma patients affected due to break in follow-ups. Additionally, COVID-19 is having a tremendous impact on eye care in the Maldives. Due to the lock down people are not able to travel from one place to the other. Air and sea transport is at standstill and people from the outlying islands are not able to visit the nearest centre for eye care. A few centers in the capital Male are offering online consultations to patients. However, this has its limitations and healthcare professionals cannot do refractions online and a detailed anterior segment and posterior segment examinations is also not possible. Thus, COVID 19 is having a significant impact on the quality and quantity of eye care in the Maldives.

Market Overview and Dynamics

The ocular drug delivery market in Asia Pacific is expected to grow US$ 5,608.56 million by 2028 from US$ 3,234.93 million in 2021. The market is estimated to grow at a CAGR of 8.2% from 2021 to 2028. Cataract, glaucoma, age-related macular degeneration, diabetic retinopathy, and unaddressed refractive error are among the leading causes of blindness or low vision. Most of the population have or had some eye disorder in their lifetime. As per the World Health Organization (WHO) report "Blindness and vision impairment" published in February 2021, around 2.2 billion people worldwide have a near or distance vision impairment. It has also estimated that the leading cause of vision loss or low vision is cataract (94 million) and uncorrected refractive errors (88.4 million). Further, the other common causes of vision loss are glaucoma (7.7 million), corneal opacities (4.2 million), diabetic retinopathy (3.9 million), and trachoma (2 million). Thus, the Burgeoning prevalence of eye disorders is likely to enhance the growth of the market.

Key Market Segments

Asia Pacific ocular drug delivery market is segmented based on technology, formulation type, disease type, end user. Based on technology, implantable ocular drug delivery systems segment accounted for the highest share in 2021. Based on formulation type, solution segment accounted for the highest share in 2021. Based on disease type, cataract segment accounted for the highest share in 2021. Based on end user hospitals segment accounted for the highest share in 2021.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on ocular drug delivery market in Asia Pacific are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are AbbVie Inc.; Bausch Health Companies Inc.; Novartis AG; Clearside Biomedical, Inc.; and Taiwan Liposome Company, Ltd. among others.

Reasons to buy report

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Asia Pacific ocular drug delivery market
• Highlights key business priorities in order to assist companies to realign their business strategies
• The key findings and recommendations highlight crucial progressive industry trends in Asia Pacific ocular drug delivery market, thereby allowing players across the value chain to develop effective long-term strategies
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
• Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the ocular drug delivery market as well as those hindering it
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution  

Asia Pacific Ocular Drug Delivery Market Segmentation

Asia Pacific Ocular Drug Delivery Market – By Technology

• Implantable Ocular Drug Delivery Systems
• Particulate Drug Delivery Systems
• Nano-Particle Drug Delivery System
• Others

Asia Pacific Ocular Drug Delivery Market – By Formulation Type

• Solution
• Ointment
• Suspension
• Emulsion
• Liposomes and Nanoparticles

Asia Pacific Ocular Drug Delivery Market – By Disease type

• Cataract
• Dry Eye Syndrome
• Macular Degeneration
• Glaucoma
• Diabetic Retinopathy
• Diabetic Macular Edema
• Others

Asia Pacific Ocular Drug Delivery Market – By End User

• Hospitals
• Ophthalmic Clinics
• Ambulatory Surgical Centers

Asia Pacific Ocular Drug Delivery Market – By Country

• Japan
• China
• India
• South Korea
• Australia
• Rest of APAC

Asia Pacific Ocular Drug Delivery Market – Companies Mentioned

• AbbVie Inc.                                              
• Bausch Health Companies Inc.            
• Novartis AG                                            
• Clearside Biomedical, Inc.                     
• Taiwan Liposome Company, Ltd.

Asia Pacific Ocular Drug Delivery Market Strategic Insights

Asia Pacific Ocular Drug DeliveryMarket Report Highlights

Asia Pacific Ocular Drug Delivery Market Country and Regional Insights